Pédiatrie II
Mon statut pour la session
À la fin de cette séance, les participants seront en mesure de faire ce qui suit:
CanMEDS: Promoteur de la santé, Expert médical
Sous sessions
Author’s Name(s): Alicia Liu, Oi Ying Wong, Man Hin Leung, Connie Lai, Thomas Lam, Wai-Ching LamAuthor’s Disclosure Block: Alicia Liu, none; Oi Ying Wong, none; Man Hin Leung, none; Connie Lai, none; Thomas Lam, none; Wai-Ching Lam, noneAbstract BodyRetinopathy of prematurity (ROP) is the leading cause of preventable childhood blindness. Tear protein biomarkers identified from next-generation label-free proteomics may offer ...
Author’s Name(s): Farnaz Javadian, Wilma Hopman, Faiza Khurshid, Christine LawAuthor’s Disclosure Block: Farnaz Javadian, none; Wilma Hopman, none; Faiza Khurshid, none; Christine Law, noneAbstract BodyPurpose: Steroid treatment can be crucial in treating morbidity and mortality in preterm infants. The literature describes differing effects of antenatal (ANS) versus postnatal steroids (PCS) in the development of retinopathy ...
Author’s Name(s): Felicia Tai, Yasmin Jindani, Kourosh SabriAuthor’s Disclosure Block: Felicia Tai, none; Yasmin Jindani, none; Kourosh Sabri, noneAbstract BodyPurpose: Retinopathy of prematurity (ROP) is a proliferative retinal vascular disease affecting many premature infants, with 5-10% of untreated ROP leading to permanent blindness. Many models currently exist for screening premature infants for treatment-requiring ROP....
